Elotuzumab, a humanized immunoglobulin IgG1 monoclonal antibody binding SLAMF7, expressed both on MM and NK cells, is the first in class mAb to be explored in MM and to show, in combination with lenalidomide and dexamethasone (Rd), a significant OS benefit in RRMM compared to Rd in phase II ELOQUENT-2 trial [8]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.